TABLE 2.
Isolates | CHDL type | Chromosome/plasmid | Resistance genes |
MIC (mg/L) |
|||||||||||||||
PIPC | S/A | TAZ/PIPC | CAZ | CFPM | IPM | MEPM | DRPM | GM | TOB | AMK | MINO | CL | CPFX | LVFX | ST | ||||
Ab-B004d-c | OXA-23 | Chromosome | blaADC-66, blaOXA-70, sul1, ant(3″)-IIa, aac(3)-IIa and blaCTX-M-15 | >64 | >8/16 | >4/64 | >16 | >16 | >8 | >8 | >8 | >8 | >8 | 8 | 0.5 | ≤2 | >2 | >4 | >38/2 |
Plasmid | dfrA1, mph(E), msr(E),tet(39), aac(3)-IId and blaOXA-23 | ||||||||||||||||||
Ab-D10a-a | OXA-23 | Chromosome | blaADC-66,blaOXA-70, sul1, ant(3″)-IIa, aac(3)-IIa and blaCTX-M-15 | >64 | >8/16 | >4/64 | >16 | >16 | >8 | >8 | >8 | >8 | >8 | 16 | 0.5 | ≤2 | >2 | >4 | >38/2 |
Plasmid | dfrA1, mph(E), msr(E), tet(39), aac(3)-IId and blaOXA-23 | ||||||||||||||||||
Ab-C102 | OXA-58 | Chromosome | ant(3″)-IIa, blaOXA-699 and blaADC-32 | 64 | 1/2 | 4/32 | 8 | 4 | 1 | 1 | 0.5 | 0.5 | 2 | 2 | ≤0.25 | ≤2 | 0.5 | ≤1 | >38/2 |
Plasmid | aph(6)-Id, aph(3″)-Ib, sul2, aph(3′)-Ia, floR and blaOXA-58 | ||||||||||||||||||
Ab-C63 | OXA-420 | Chromosome | blaADC-87, blaOXA-51 and ant(3″)-IIa | >64 | 8/16 | >4/64 | 4 | 8 | 4 | 4 | 4 | >8 | >8 | 2 | 0.5 | 4 | >2 | >4 | >38/2 |
Plasmid | mph(E), msr(E), tet(39), dfrA20, sul2, aph(6)-Id, aph(3″)-Ib, blaOXA-420, ant(2″)-Ia and aph(3’)-Ia |
Abbreviations: PIPC, piperacillin; S/A, ampicillin-sulbactam; TAZ/PIPC, piperacillin-tazobactam; CAZ, ceftazidime; CFPM, cefepime; IPM, imipenem; MEPM, meropenem; DRPM, doripenem; GM, gentamycin; TOB, tobramycin; AMK, amikacin; MINO, minocycline; CL, colistin, CPFX, ciprofloxacin; LVFX, levofloxacin; ST, trimethoprim-sulfamethoxazole.